Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORT RUN AF
2024-516374-29-00Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in systemic embolism, ischemic stroke and atrial arrhythmia comparing Rivaroxaban with Standard of care (2 arms). Primary endpoints: First ischemic stroke or peripheral embolism and Major bleeding. Started Apr 2023; status: completed.
02
Drugs
rivaroxaban
03
Conditions
systemic embolismischemic strokeatrial arrhythmia
Beyond the preview
Go deeper on 2024-516374-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516374-29-00.